Investor Overview
A revenue business today.
A wellness technology tomorrow.
Igniton is a revenue-generating premium wellness brand today — and a quantum-wellness technology platform tomorrow. Backed by a proven founder and majority-owned by a public company (Gaia Inc., NASDAQ: GAIA).
The Thesis
A de-risked business with venture-scale upside.
Proven operator
Founder Jirka Rysavy's track record — Corporate Express ($4.7B, acquired by Staples), the Wild Oats lineage, and Gaia Inc. (NASDAQ: GAIA) — de-risks execution.
Real traction
A revenue-generating, subscription-led supplement business with published university studies and a public-company parent. Financial figures pending verification.
A defensible moat
The enhancement process and ignitons IP, paired with peer-reviewed science and a 30-year research lineage — not just what's in it, but what's been done to it.
Venture upside
The platform roadmap — from studied formulas today to an in-home igniton-field device and the HIT coherence chair — plus Gaia's owned, conscious-media audience.
The Moat
Not just what’s in it. What’s been done to it.
The defensible asset is the process, not the ingredient list. In an otherwise commodity category, Igniton’s cold-plasma charging alters each ingredient’s molecular state before encapsulation — the step competitors can’t easily replicate, and the reason head-to-head studies favor the charged formula over the same uncharged inputs.
Commodity inputs, proprietary process
The ingredients are ordinary GRAS compounds; the moat is what’s done to them. Cold-plasma charging puts each into an “excited” state before encapsulation — the formula holds, the enhancement is the variable.
A lower effective dose
The company reports 80–90% lower effective dose required, with stronger effect at lower concentration as measured in GDV testing.
Measured, not asserted
Gas Discharge Visualization (GDV) — the same instrumentation used in the published Igniton trials — is used to quantify the charged state.
From particle physics to the human body
Framed as Igniton’s framework, not settled physics.
- 1990s
Discovery and characterization of the eNPQ quasi-particle later named “ignitons.”
- 1995
Laboratory established in Switzerland; much of the measurement hardware rented from CERN.
- 2023
Cold-plasma production operation established in Louisville, Colorado.
- 2024–25
University-led trials completed and published in peer-reviewed journals.
IP & moat
The source describes a patented process embedding ignitons into the molecules, plus a proprietary cold-plasma and laser-photonics system developed over 30 years, and manufacturing know-how.
Patent / IP status:Pending verification
'Ignitons,' 'coherence,' and related concepts represent Igniton's framework and are not presented as established scientific consensus.
The Portfolio
Four validated formulas. One revenue foundation.
The current product line is the de-risked, cash-generating base of the business. Each formula carries its own study tier and exact figures. The Cognition + Longevity pairing is the validated top revenue line.
Products are sold to consumers at igniton.com ↗. No pricing or checkout appears on this investor site.
IgniCognition™
University study, published in a peer-reviewed journal
The flagship line and deepest evidence base in the portfolio — and half of the validated Cognition + Longevity revenue pairing.
- +83% quality of mental performance**
- +51% sustained attention**
- +28% short-term memory**
- +25% operational memory**
Valverde R. et al., 2023 — HSOA Journal of Alternative, Complementary & Integrative Medicine (Concordia University). 90-day RCT, 80 subjects, 3 arms incl. placebo.
IgniLongevity™
University study, published in a peer-reviewed journal
The systemic-inflammation and longevity formula — peer-reviewed across three independent measurement methods, and the other half of the top revenue pairing.
- −37% IL-6**
- −28% CRP**
- −13% GGT**
- −8/9% blood pressure**
International Journal of Studies in Psychology, DOI 10.38140/ijspsy.v5i1.1616. 30-day RCT, 70 subjects, 3 arms, 3 independent measurement methods.
IgniPeptide Eye Serum™
Independent clinical study
The topical entry point into skincare — Igniton-charged EGF, validated by an independent contract-research clinical trial.
- +52% skin hydration*
- +30% barrier function in 24h*
- 100% of subjects improved*
- 34% better barrier vs. non-charged*
8-week independent clinical trial by ALS Global (CRO), 52 healthy female subjects (Corneometer, Cutometer, TEWL).
IgniREM Sleep™
A study (initial)
The sleep formula and newest pipeline entry — an early-stage study showing increased REM versus placebo, expanding the line.
- +25% more REM vs. placebo**
- Fewer wake-ups: 2.6 → 1.2 / night**
- More sleep: 6.3 → 7.1 hrs**
Open, randomized, enhanced-vs-placebo trial: 14 days vs. 7-day baseline, 60 healthy people aged 40–76.
** These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Made in Colorado, USA
A premium ritual, engineered to work.
Traction & Validation
Backed by studies, not marketing.
Business metrics
Scientific validation
- Three peer-reviewed published studies (Cognition, post-COVID Cognition, Longevity/Stress).
- Additional independent clinical study (Peptide) and an initial study (REM).
- Journals: HSOA J. Alternative, Complementary & Integrative Medicine; Int’l J. Studies in Psychology.
- Medical & scientific advisory board (see Team).
“This is the most important new breakthrough supplement for longevity — and after 90 days on Igniton’s brain formula, I didn’t just use it, I invested in it.”
Attribution pending permission for investor use.
Three 2025 COVR Visionary Awards
Coalition of Visionary Resources (COVR) — Mind-Body-Spirit marketplace
Awaiting documentation (omitted until supplied)
- “As seen in” publication names
- Specific customer-review counts (theme defaults were placeholders)
The Company
A real business with a public-company parent.
- Igniton, Inc. is a Colorado C corporation.
- Headquarters in Colorado on a 12-acre campus near Boulder.
- Company has cash and no debt.
- Bio-Well, a biophotonic company, is a majority-owned subsidiary.
The Gaia relationship
Igniton is majority-owned by Gaia Inc. (NASDAQ: GAIA), a publicly traded conscious-media company founded by Jirka Rysavy. Gaia’s audience is a built-in distribution engine.
Gaia ownership:Pending exact %
Business model
Premium direct-to-consumer supplements, subscription-led, expanding into a technology platform. Cap-table summary and use of funds available to qualified investors on request.
Roadmap
From studied formulas to a wellness platform.
This site contains forward-looking statements, including regarding future products (e.g., in-home devices and the HIT chair), technology, and business plans. These are subject to risks and uncertainties; actual results may differ materially. Nothing here is a promise or guarantee of future performance.
The studied formulas
A revenue-generating, subscription-led supplement line with published university studies — the de-risked foundation of the business.
In-home igniton-field device
A forward-looking vision to bring the enhancement technology into the home as a device. Exploratory; not committed, dated, or available.
The HIT coherence chair
Holoton-Igniton Therapy (HIT): a coherence chair with Bio-Well monitoring, envisioned for clinics, performance, and longevity. A long-range vision, not a product commitment.
Investor Relations
Let’s talk.
For the investor overview, data room access, or a conversation with the team, reach out to investor relations.
Email investor relationsinvestors@ignitoninc.com
This website is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. Any offering will be made only to qualified/accredited investors through definitive offering documents.